Par

The Aim 100 2023: 30 to 21

30. Ergomed 
Biotech company valuations came crashing down to earth as the threat from Covid-19 receded and interest rates rose. Naturally, this was not a welcome development for retail investors – but it undoubtedly created M&A opportunities. Pharmace…